|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar
|
|
2
|
Burger M, Catto JW, Dalbagni G, Grossman
HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C,
Shariat S, et al: Epidemiology and risk factors of urothelial
bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar
|
|
3
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar
|
|
4
|
Jacobs BL, Lee CT and Montie JE: Bladder
cancer in 2010: How far have we come? CA Cancer J Clin. 60:244–272.
2010. View Article : Google Scholar
|
|
5
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar
|
|
6
|
Vaishampayan U: Systemic therapy of
advanced urothelial cancer. Curr Treat Options Oncol. 10:256–266.
2009. View Article : Google Scholar
|
|
7
|
King LM and Francomano CA:
Characterization of a human gene encoding nucleosomal binding
protein NSBP1. Genomics. 71:163–173. 2001. View Article : Google Scholar
|
|
8
|
Rochman M, Malicet C and Bustin M:
HMGN5/NSBP1: A new member of the HMGN protein family that affects
chromatin structure and function. Biochim Biophys Acta. 1799:86–92.
2010. View Article : Google Scholar
|
|
9
|
Shi Z, Tang R, Wu D and Sun X: Research
advances in HMGN5 and cancer. Tumour Biol. 37:1531–1539. 2016.
View Article : Google Scholar
|
|
10
|
Gan Y, Tan J, Yang J, Zhou Y, Dai Y, He L,
Yao K and Tang Y: Knockdown of HMGN5 suppresses the viability and
invasion of human urothelial bladder cancer 5637 cells in vitro and
in vivo. Med Oncol. 32:1362015. View Article : Google Scholar
|
|
11
|
Yao K, He L, Gan Y, Zeng Q, Dai Y and Tan
J: MiR-186 suppresses the growth and metastasis of bladder cancer
by targeting NSBP1. Diagn Pathol. 10:1462015. View Article : Google Scholar
|
|
12
|
Haslehurst AM, Koti M, Dharsee M, Nuin P,
Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, et al: EMT
transcription factors snail and slug directly contribute to
cisplatin resistance in ovarian cancer. BMC Cancer. 12:912012.
View Article : Google Scholar
|
|
13
|
Zhao J, Dong D and Sun L, Zhang G and Sun
L: Prognostic significance of the epithelial-to-mesenchymal
transition markers e-cadherin, vimentin and twist in bladder
cancer. Int Braz J Urol. 40:179–189. 2014. View Article : Google Scholar
|
|
14
|
Zhu H, Yun F, Shi X and Wang D: VEGF-C
inhibition reverses resistance of bladder cancer cells to cisplatin
via upregulating maspin. Mol Med Rep. 12:3163–3169. 2015.
View Article : Google Scholar
|
|
15
|
Gan Y, Wang Y, Tan Z, Zhou J, Kitazawa R,
Jiang X, Tang Y and Yang J: TDRG1 regulates chemosensitivity of
seminoma TCam-2 cells to cisplatin via PI3K/Akt/mTOR signaling
pathway and mitochondria-mediated apoptotic pathway. Cancer Biol
Ther. 17:741–750. 2016. View Article : Google Scholar
|
|
16
|
West KA, Castillo SS and Dennis PA:
Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar
|
|
17
|
Zhou X, Yuan B, Yuan W, Wang C, Gao R and
Wang J: The expression and clinical significance of high mobility
group nucleosome binding domain 5 in human osteosarcoma. Tumour
Biol. 35:6539–6547. 2014. View Article : Google Scholar
|
|
18
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar
|
|
19
|
Liang W, Hao Z, Han JL, Zhu DJ, Jin ZF and
Xie WL: CAV-1 contributes to bladder cancer progression by inducing
epithelial-to-mesenchymal transition. Urol Oncol. 32:855–863. 2014.
View Article : Google Scholar
|
|
20
|
Wissmann C and Detmar M: Pathways
targeting tumor lymphangiogenesis. Clin Cancer Res. 12:6865–6868.
2006. View Article : Google Scholar
|
|
21
|
Chen H, Guan R, Lei Y, Chen J, Ge Q, Zhang
X, Dou R, Chen H, Liu H, Qi X, et al: Lymphangiogenesis in gastric
cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis. BMC Cancer.
15:1032015. View Article : Google Scholar
|
|
22
|
Gerlitz G: HMGNs, DNA repair and cancer.
Biochim Biophys Acta. 1799:80–85. 2010. View Article : Google Scholar
|
|
23
|
Rochman M, Postnikov Y, Correll S, Malicet
C, Wincovitch S, Karpova TS, McNally JG, Wu X, Bubunenko NA,
Grigoryev S, et al: The interaction of NSBP1/HMGN5 with nucleosomes
in euchromatin counteracts linker histone-mediated chromatin
compaction and modulates transcription. Mol Cell. 35:642–656. 2009.
View Article : Google Scholar
|
|
24
|
Wahafu W, He ZS, Zhang XY, Zhang CJ, Yao
K, Hao H, Song G, He Q, Li XS and Zhou LQ: The nucleosome binding
protein NSBP1 is highly expressed in human bladder cancer and
promotes the proliferation and invasion of bladder cancer cells.
Tumour Biol. 32:931–939. 2011. View Article : Google Scholar
|
|
25
|
Burgering BM and Coffer PJ: Protein kinase
B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.
Nature. 376:599–602. 1995. View
Article : Google Scholar
|
|
26
|
Nordentoft I, Dyrskjot L, Bodker JS, Wild
PJ, Hartmann A, Bertz S, Lehmann J, Orntoft TF and
Birkenkamp-Demtroder K: Increased expression of transcription
factor TFAP2alpha correlates with chemosensitivity in advanced
bladder cancer. BMC Cancer. 11:1352011. View Article : Google Scholar
|
|
27
|
Yang L, Shi T, Liu F, Ren C, Wang Z, Li Y,
Tu X, Yang G and Cheng X: REV3L, a promising target in regulating
the chemosensitivity of cervical cancer cells. PloS One.
10:e01203342015. View Article : Google Scholar
|
|
28
|
He J, Liu C, Wang B, Li N, Zuo G and Gao
D: HMGN5 blockade by siRNA enhances apoptosis, suppresses invasion
and increases chemosensitivity to temozolomide in meningiomas. Int
J Oncol. 47:1503–1511. 2015. View Article : Google Scholar
|
|
29
|
Guo Z, Zhang X, Li X, Xie F, Su B, Zhang M
and Zhou L: Expression of oncogenic HMGN5 increases the sensitivity
of prostate cancer cells to gemcitabine. Oncol Rep. 33:1519–1525.
2015. View Article : Google Scholar
|
|
30
|
Zhang HY, Zhang PN and Sun H: Aberration
of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its
implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol
Reprod Biol. 146:81–86. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun D, Sawada A, Nakashima M, Kobayashi T,
Ogawa O and Matsui Y: MK2206 potentiates cisplatin-induced
cytotoxicity and apoptosis through an interaction of inactivated
Akt signaling pathway. Urol Oncol. 33:111.e17–111.e26. 2015.
View Article : Google Scholar
|
|
32
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nicholson DW and Thornberry NA: Apoptosis.
Life and death decisions. Science. 299:214–215. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Estaquier J, Vallette F, Vayssiere JL and
Mignotte B: The mitochondrial pathways of apoptosis. Adv Exp Med
Biol. 942:157–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
